Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss CAMBRIDGE, Mass. & SUMMIT, N.J.– Feb. 20, 2008 – Acceleron Pharma, Inc. and Celgene Corporation today announced a worldwide strategic collaboration for the joint development and
View HTML
Toggle Summary Acceleron Pharma Receives Grant for ACE-011 from the Multiple Myeloma Research Foundation
Acceleron Pharma Receives Grant for ACE-011 from the Multiple Myeloma Research Foundation Cambridge, Mass. – January 23, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that it
View HTML
Toggle Summary Acceleron Pharma to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
Acceleron Pharma to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference Cambridge, Mass. – November 20, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that
View HTML
Toggle Summary Acceleron Pharma to Present at the Massachusetts Biotechnology Council’s 9th Annual MASS Opportunities Investment Conference
Acceleron Pharma to Present at the Massachusetts Biotechnology Council’s 9th Annual MASS Opportunities Investment Conference Cambridge, Mass. – November 1, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and
View HTML
Toggle Summary BioWorld Today: Acceleron Series C Gets $31M for Bone, Muscle Growth Bids
BioWorld Today: Acceleron Series C Gets $31M for Bone, Muscle Growth Bids BioWorld Today, October 31, 2007
View HTML
Toggle Summary Acceleron Pharma to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Acceleron Pharma to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference Cambridge, Mass. – October 31, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced
View HTML
Toggle Summary Acceleron Pharma Completes $31M Series C Financing
Top venture syndicate invests to advance expanding pipeline of products that modulate tissue growth and repair
View HTML
Toggle Summary Acceleron Pharma’s ACE-031 Increases Muscle Mass In a Preclinical Model of Glucocorticoid-induced Muscle Loss
Findings Substantiate Potential of ACE-031 in Treatment of Neuromuscular Disease and Cancer-related Muscle Loss
View HTML
Toggle Summary Technology Review: Mimicking the Massively Muscular
Technology Review: Mimicking the Massively Muscular Link to article
View HTML
Toggle Summary Acceleron Pharma Website Awarded “Pharmaceutical Industry Standard of Excellence” by the Web Marketing Association
Acceleron Pharma Website Awarded “Pharmaceutical Industry Standard of Excellence” by the Web Marketing Association Cambridge, Mass. – October 4, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle,
View HTML